Cognitive Augmentation Via Multimodal Sensing and Auricular Neurostimulation (CAMSAN)

CAMSAN: Cognitive Augmentation Via Multimodal Sensing and Auricular Neurostimulation

The goal of this clinical trial is to extend this period of optimal cognitive performance by applying neurostimulation to buffer health volunteers against the effects of increased levels of stress, distraction, and cybersickness. The main questions it aims to answer are:

• Can we use OpenBCI's head-mounted Galea biosensor + eXtended Reality (XR) platform to measure participants' cognitive state in relation to stress, attention and cybersickness?
• How does applying external neurostimulation via Spark Biomedical's Sparrow Link transcutaneous auricular neurostimulation (tAN) system enhance cognitive performance with a closed-loop interface that automatically applies neurostimulation as a function of physiologically determined stress, attention, and cybersickness metrics?

Researchers will compare the active neurostimulation group to the sham neurostimulation group to see if cognitive performance is improved with stimulation.

Participants will complete 4 virtual reality tasks in the lab:

• 2 tasks related to attention - Flanker and Gradual-onset Continual Performance Task (GradCPT)
• The Multi-Attribute Task Battery (MATB)
• A cybersickness task
• And a baseline session before each task
• Neurostimulation intervention will occur in response to cognitive states

Study Overview

• Status: Completed
• Conditions: Healthy; Cognitive Change; Effects of External Neurostimulation on Cognition
• Intervention / Treatment: Device: Sham Stimulation; Device: Active Neurostimulation

Detailed Description

The objective of this study is to determine if active tAN stimulation can form a closed-loop system with the Galea biosensing headset to enhance cognitive performance. The study is designed as a randomized, blinded, sham-controlled trial to test the effects of active tAN stimulation in cognitive stimulation tasks (Flanker task, GradCPT, MATB and cybersickness tasks) towards improvement of cognitive performance.

The study occurs in three phases.

• Phase I is designed to establish a quantifiable relationship between biometric data and cognitive states (cognitive load, stress, attention and cybersickness) under cognitive stimulation tasks (Flanker task, GradCPT, MATB and cybersickness tasks).
• Phase II involves evaluation of manual tAN to affect cognitive state in an open-loop paradigm.
• The third phase involves using the cognitive state quantification from Phase I, and the quantified effects of tAN discovered in Phase II to examine a closed-loop cognitive augmentation system.

Preliminary Cognitive State Assessment:

Phase I of the experiment will establish a cognitive task performance baseline, and also allow for quantification of cognitive state metrics based on biomarkers. Participants will perform the following tasks: Flanker Task, GradCPT, MATB, and a cybersickness stimulation task. Each of these tasks have different quantification and scoring systems to evaluate performance, and each aim to induce different cognitive stimulation. Before each task, an idle baseline of cognitive state is recorded.

Open-loop Intervention:

In Phase II, all participants (Groups 1-2) will undergo the same set of tasks, this time while wearing the Sparrow Link tAN device, and Group 1 will experience active tAN, controlled by the investigator to determine optimal settings for affecting cognitive state.

Closed-loop Intervention:

In Phase III, the information on quantifying cognitive state determined in phase I and information on affecting cognitive state determined in phase II will be used to create a closed-loop intervention system using active tAN (Group 1 only), triggered based on conditions determined by the investigating team. Both groups will undergo the same set of tasks as in Phase I and Phase II, but Group 1 will receive active tAN and Group 2 will not.

Tasks Experimental paradigms and mechanisms that have been shown to induce stress, loss of attention, and cybersickness will be used to elicit physiological responses from study participants. These responses will be used to generate data for automatic characterization of the target cognitive states, determine how different levels of manual tAN affects these states, and test the efficacy of a closed-loop neurostimulation system. These paradigms and mechanisms are described below.

Multi-Attribute Task Battery (MATB) The Multi-Attribute Task Battery is a computer-based task designed to evaluate operator performance and workload. MATB provides a benchmark set of tasks analogous to activities that aircraft crew members perform in flight, although it can also be used by non-pilot individuals. The MATB requires simultaneous performance of monitoring dynamic resource management, and task tracking. The simultaneous performance of multiple tasks is a central feature of the MATB, and is the feature that is consistent with most operational systems, making it useful as a research platform.

Flanker Task The flanker task can be used to measure processing and selective attention (Eriksen, 1974). The flanker task requires participants to respond to a central target stimulus while ignoring flanking stimuli that may or may not be congruent with the target stimulus (Eriksen, 1974). These tasks become more challenging over time either by decreasing the time allowed for reactions or by introducing more conflicting information. A subject's responses and error rate can be used to gauge their attention and stress levels.

GradCPT A continuous performance task requires the participants to respond to frequent stimuli and inhibit responding to infrequent stimuli (Robertson, et al., 1997). GradCPT eliminates the offsets and onsets of visual stimuli between trials by using gradual transitions. As a result, GradCPT is more dependent on internal attention control and useful for studying sustained attention processes using physiological methods. The GradCPT task is used to test a subject's sustained and selective attention as well as response inhibition. Insufficient attention to tasks can result in unintended or incorrect inputs. Images show the first image transitioning to the second at 100%, 75%, 50%, 25% and 0% image coherence. Participants are required to press a button each time a city scene is presented (90% of trials) and withhold responses when infrequent mountain scenes are presented on the remaining 10% of trials (Fortenbaugh, et al., 2017).

Cybersickness Stimulation Mechanisms Cybersickness relates to the tendency of some users to exhibit symptoms similar to classical motion sickness both during and after a virtual reality (VR) experience. It is distinct from motion sickness in that the user is often stationary but has a compelling sense of self motion as a result of the immersive visual aspects of the simulation (LaViola Jr, 2000). The symptoms of cybersickness include dizziness, nausea, and lightheadedness (Davis & Nalivaiko, 2014), and there are several factors that are known to induce cybersickness including latency (Stauffert et al. 2020) and loss of control (Davis & Nalivaiko, 2014). Prevalence of sensitivity to cybersickness ranges from 20-95% with immersive VR experiences (Yildirim, 2020).

Sensing Technologies This section describes the technologies that will be used during the experiment to record physiological responses to stimuli and characterize cognitive state metrics.

Electroencephalography (EEG) Electroencephalography (EEG) records brain electrical activity via placement of electrodes on the scalp. One major advantage of using EEG is that it is noninvasive, meaning it is a safe and low-risk method for studying brain activity.

The Galea biosensing suite supports ten active EEG electrodes and two passive EEG electrodes. The ten active electrodes are located along the midline and in the frontal, parietal and occipital lobes. Specifically, their locations are F1, F2, C3, CZ, C4, P3, P4, PZ, O1, O2 as denoted by the 10-10 system for EEG recording. The two passive electrodes are located in the headset face mask and measure the Fp1 and Fp2 locations as denoted by the 10-10 system. The device has two attached clips that attach to the ears of the user. These ear clips provide common-mode signal rejection and serve as a reference voltage for the EEG electrodes.

Face Electromyography (EMG) Electromyography (EMG) relates to the measurement of muscles and the nerve cells (motor neurons) that control them. To measure EMG, electrodes are placed on the skin or inserted into the muscle to detect electrical activity. The resulting signals are then analyzed to provide information about the functioning of muscles and nerves.

The Galea biosensing suite includes dry EMG electrodes around a face mask that attaches to the XR component of the headset. These electrodes measure facial muscle activity and allow for estimation of face poses when the face is covered by the XR headset. Three pairs of electrodes are placed above the eyebrows in different orientations in order to target the Frontalis muscles that raise the eyebrows, as well as the Depressor Glabellae, Depressor Supercilli, and Currugator muscles that allow the eyebrows to lower. Additional electrode pairs are placed on each of the cheeks to target the Zygomatic Major and Zygomatic Minor muscles that allow the lips and cheeks to move. The electrodes are standard dry, flat electrodes coated in Ag/AgCl.

Photoplethysmography (PPG) Photoplethysmography (PPG) is a non-invasive method of measuring blood flow in blood vessels close to the skin's surface. PPG provides information about the volume of blood in a particular area and can be used to infer the pulse rate and oxygen saturation levels. PPG can be used to measure pulse rate variability, which closely approximates heart rate variability (Chuang et al., 2015).

A PPG sensor is integrated into one of the ear clips attached to the Galea biosensing suite. The clip is placed on the earlobe, which results in very high signal-to-noise (SNR) signals, relative to other locations and is a sufficient replacement for heart rate monitoring when compared to electrocardiogram (Vescio et al., 2018; Weiler et al., 2017).

Electrodermal Activity (EDA) Electrodermal activity (EDA) refers to changes in the electrical conductance of the skin which are caused by changes in sweat gland activity. EDA can be measured by attaching electrodes to the skin and recording changes in skin conductance or impedance. Both methods provide adequate information on the changes in skin conductance. Sweat gland activity is often associated with increased emotional arousal, particularly with stress and anxiety, and EDA is a well established physiological measure that is used to assess changes in arousal, attention and emotional states (Leiner et al., 2012). However, the limitation of EDA is that it only provides information about changes in skin conductance relative to a baseline, and does not indicate what specific cognitive state the change in conductance is linked to.

Galea measures EDA from the forehead, which provides a similar level of information to more peripheral measurement locations (Hossain et al., 2022).

Electrooculography (EOG) The Galea biosensing suite supports integrated EOG, which measures eye electrical activity. The system detects eye movements along the vertical and horizontal axes. When these movements occur, the eye movement acts as a dipole and causes large measurable fluctuations that can be recorded. The Galea's EOG sensors use the same flat Ag/AgCl electrodes that the EMG face sensors. They are placed above and below the right eye for vertical EOG and on the outside periphery of the left and right eyes for horizontal EOG.

Eye Tracking and Pupillometry Eye gaze tracking is achieved using infrared imaging sensors that map eye movements in real time. Pupillometry is the measure of pupil size changes in response to different scenarios or stimuli.

The Galea biosensing suite includes an integrated Varjo XR-3 head-mounted display (HMD). These HMDs use infrared eye cameras to track gaze, eye movement, and pupillometry. The integrated eye gaze tracking and pupillometry system samples at 200 Hz and is able to pick up subtle shifts in attention and concentration.

Neurostimulation Techniques Transcutaneous auricular neurostimulation (tAN) is a paradigm which targets both the trigeminal and vagus nerves on the auricle. tAN delivers mild electrical stimulation to modulate several cranial nerve branches in key dermatome regions through a small non-invasive device placed over the left ear (auricle). These regions cover or are adjacent to the afferent sensory innervation of several cranial nerves (V, VII, IX, X) and occipital nerves.

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • New York
    • Brooklyn, New York, United States, 11222
      • OpenBCI

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy human subjects between the ages of 18 and 55
• Normal color vision and near visual acuity of 20/30 without correction.
• Participant is right-hand dominant
• Proficient in the English language
• Ability to understand the explanations and instructions given by the study personnel

Exclusion Criteria:

• Participant presents current evidence of an uncontrolled and/or clinically significant medical condition or psychiatric condition
• Participant is participating in another interventional trial within 90 days prior to or throughout duration of trial
• Participant has a prior diagnosis of post-traumatic stress disorder, acute stress disorder, or generalized anxiety disorder
• Participant has a diagnosis of attention deficit hyperactivity disorder (ADHD) and/or is currently taking medications for the treatment of ADHD.
• Current or recent history of substance abuse or drug dependence including nicotine and alcohol, or use of mind-altering drugs in the past 30 days.
• Participant has abnormal ear anatomy, ear infection present, or ear piercing that could interfere with stimulation
• Participant has a recent history of epileptic seizures; including photosensitive epilepsy
• Participant has a recent history of neurologic diseases or traumatic brain injury
• Participant has presence of implanted medical devices (e.g., pacemakers, cochlear prostheses, neurostimulators)
• Females who are pregnant or lactating
• Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants are risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
• Sensitivity to bright screens or virtual reality displays
• Recent history of neurological and psychiatric disease/disorder

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Sham Comparator: Sham Stimulation; The sham group will receive a device but no stimulation will be delivered.	Device: Sham Stimulation; Modulation of stimulation frequency and amplitudes outside of the known physiological effective ranges during intervention periods.
Experimental: Active tAN; This group receives active neurostimulation at different intervals, amplitudes, and frequencies via the Sparrow Link device.	Device: Active Neurostimulation; The stimulation frequency, pulse width, and amplitude will be varied in order to determine the optimal stimulation conditions for elongating the period of peak subject performance during the experimental tasks. Amplitude, pulse width, and frequency meet or exceed International Electrotechnical Commission (IEC) 60601-2-10:2016 requirements. The amplitude range specified is selectable for either channel with any frequency and pulse width combination. We will test an amplitude range of 0 mA - 5.0 mA. We will test a frequency range of 1 Hz - 150 Hz. We will test a pulse width range of 50 μs - 750 μs. The study coordinator should apply neurostimulation when the reported cognitive state metric corresponding to the performance task reaches different thresholds. These thresholds will be determined before execution of the study and will be chosen to maximize the likelihood of discovering an optimal trigger for neurostimulation based on reported cognitive state.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Flanker Task Performance	Performance will be measured by number of correct responses and reaction time. Specially we will look at mean change in score (percentage of correct responses) and reduction in reaction time.	Baseline, pre-intervention, and during the intervention phases
GradCPT Task Performance	Performance will be measured by number of correct responses and reaction time. Specially we will look at mean change in score (percentage of correct responses) and reduction in reaction time.	Baseline, pre-intervention, and during the intervention phases
MATB Task Performance	Performance will be measured by number of correct responses and performance in the resource management task. Specially we will look at mean task completion percentage and root mean squared error in resource management task.	Baseline, pre-intervention, and during the intervention phases
Cybersickness Task Performance	Performance will be measured by time in experiment. Specifically we will look at mean time before cybersickness symptoms present and mean time before participants voluntarily discontinue the experiment.	Baseline, pre-intervention, and during the intervention phases

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bedford Work Scale Responses	We will also look at the mean change in Bedford Work Scale (from 1-10) from baseline indicating change in perceived workload in the MATB task.	Baseline, pre-intervention, and during the intervention phases
Simulator Sickness Questionnaire (SSQ) Responses	We will also look at the mean change in SSQ score (each question scored on a 1-4 scale).	Baseline, pre-intervention, and during the intervention phases
Baxter Retching Faces (BARF) Responses	We will also look at the mean change in BARF score during cybersickness task (scored 0-10).	Baseline, pre-intervention, and during the intervention phases

Collaborators and Investigators

• Sponsor: OpenBCI
• Collaborators: Spark Biomedical, Inc.
• Investigators: Principal Investigator: Musa Mahmood, PhD, OpenBCI; Study Director: Zoe Steine-Hanson, PhD, OpenBCI; Study Chair: Alejandro Covalin, PhD, Spark Biomedical; Study Chair: Navid Khodaparast, PhD, Spark Biomedical; Study Chair: Conor Russomanno, Masters, OpenBCI

Publications and helpful links

General Publications

• McDuff D, Gontarek S, Picard R. Remote measurement of cognitive stress via heart rate variability. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:2957-60. doi: 10.1109/EMBC.2014.6944243.
• Kaniusas E, Kampusch S, Tittgemeyer M, Panetsos F, Gines RF, Papa M, Kiss A, Podesser B, Cassara AM, Tanghe E, Samoudi AM, Tarnaud T, Joseph W, Marozas V, Lukosevicius A, Istuk N, Sarolic A, Lechner S, Klonowski W, Varoneckas G, Szeles JC. Current Directions in the Auricular Vagus Nerve Stimulation I - A Physiological Perspective. Front Neurosci. 2019 Aug 9;13:854. doi: 10.3389/fnins.2019.00854. eCollection 2019.
• Robertson IH, Manly T, Andrade J, Baddeley BT, Yiend J. 'Oops!': performance correlates of everyday attentional failures in traumatic brain injured and normal subjects. Neuropsychologia. 1997 Jun;35(6):747-58. doi: 10.1016/s0028-3932(97)00015-8.
• Esterman M, Noonan SK, Rosenberg M, Degutis J. In the zone or zoning out? Tracking behavioral and neural fluctuations during sustained attention. Cereb Cortex. 2013 Nov;23(11):2712-23. doi: 10.1093/cercor/bhs261. Epub 2012 Aug 31.
• Armstrong T, Olatunji BO. Eye tracking of attention in the affective disorders: a meta-analytic review and synthesis. Clin Psychol Rev. 2012 Dec;32(8):704-23. doi: 10.1016/j.cpr.2012.09.004. Epub 2012 Sep 20.
• De Smet S, Ottaviani C, Verkuil B, Kappen M, Baeken C, Vanderhasselt MA. Effects of non-invasive vagus nerve stimulation on cognitive and autonomic correlates of perseverative cognition. Psychophysiology. 2023 Jun;60(6):e14250. doi: 10.1111/psyp.14250. Epub 2023 Jan 22.
• Broncel A, Bocian R, Klos-Wojtczak P, Kulbat-Warycha K, Konopacki J. Vagal nerve stimulation as a promising tool in the improvement of cognitive disorders. Brain Res Bull. 2020 Feb;155:37-47. doi: 10.1016/j.brainresbull.2019.11.011. Epub 2019 Nov 29.
• Badran BW, Dowdle LT, Mithoefer OJ, LaBate NT, Coatsworth J, Brown JC, DeVries WH, Austelle CW, McTeague LM, George MS. Neurophysiologic effects of transcutaneous auricular vagus nerve stimulation (taVNS) via electrical stimulation of the tragus: A concurrent taVNS/fMRI study and review. Brain Stimul. 2018 May-Jun;11(3):492-500. doi: 10.1016/j.brs.2017.12.009. Epub 2017 Dec 29.
• Allen J. Photoplethysmography and its application in clinical physiological measurement. Physiol Meas. 2007 Mar;28(3):R1-39. doi: 10.1088/0967-3334/28/3/R01. Epub 2007 Feb 20.
• Sharon O, Fahoum F, Nir Y. Transcutaneous Vagus Nerve Stimulation in Humans Induces Pupil Dilation and Attenuates Alpha Oscillations. J Neurosci. 2021 Jan 13;41(2):320-330. doi: 10.1523/JNEUROSCI.1361-20.2020. Epub 2020 Nov 19.
• Kiryu T, So RH. Sensation of presence and cybersickness in applications of virtual reality for advanced rehabilitation. J Neuroeng Rehabil. 2007 Sep 25;4:34. doi: 10.1186/1743-0003-4-34.
• Ylikoski J, Markkanen M, Pirvola U, Lehtimaki JA, Ylikoski M, Jing Z, Sinkkonen ST, Makitie A. Stress and Tinnitus; Transcutaneous Auricular Vagal Nerve Stimulation Attenuates Tinnitus-Triggered Stress Reaction. Front Psychol. 2020 Sep 17;11:570196. doi: 10.3389/fpsyg.2020.570196. eCollection 2020.
• Yasemin M, Sarikaya MA, Ince G. Emotional State Estimation using Sensor Fusion of EEG and EDA. Annu Int Conf IEEE Eng Med Biol Soc. 2019 Jul;2019:5609-5612. doi: 10.1109/EMBC.2019.8856895.
• Wierda SM, van Rijn H, Taatgen NA, Martens S. Pupil dilation deconvolution reveals the dynamics of attention at high temporal resolution. Proc Natl Acad Sci U S A. 2012 May 29;109(22):8456-60. doi: 10.1073/pnas.1201858109. Epub 2012 May 14.
• Vescio B, Salsone M, Gambardella A, Quattrone A. Comparison between Electrocardiographic and Earlobe Pulse Photoplethysmographic Detection for Evaluating Heart Rate Variability in Healthy Subjects in Short- and Long-Term Recordings. Sensors (Basel). 2018 Mar 13;18(3):844. doi: 10.3390/s18030844.
• Trevino M, Zhu X, Lu YY, Scheuer LS, Passell E, Huang GC, Germine LT, Horowitz TS. How do we measure attention? Using factor analysis to establish construct validity of neuropsychological tests. Cogn Res Princ Implic. 2021 Jul 22;6(1):51. doi: 10.1186/s41235-021-00313-1.
• Solhjoo S, Haigney MC, McBee E, van Merrienboer JJG, Schuwirth L, Artino AR Jr, Battista A, Ratcliffe TA, Lee HD, Durning SJ. Heart Rate and Heart Rate Variability Correlate with Clinical Reasoning Performance and Self-Reported Measures of Cognitive Load. Sci Rep. 2019 Oct 11;9(1):14668. doi: 10.1038/s41598-019-50280-3.
• Ruhnau P, Zaehle T. Transcranial Auricular Vagus Nerve Stimulation (taVNS) and Ear-EEG: Potential for Closed-Loop Portable Non-invasive Brain Stimulation. Front Hum Neurosci. 2021 Jun 14;15:699473. doi: 10.3389/fnhum.2021.699473. eCollection 2021.
• Morton J, Zheleva A, Van Acker BB, Durnez W, Vanneste P, Larmuseau C, De Bruyne J, Raes A, Cornillie F, Saldien J, De Marez L, Bombeke K. Danger, high voltage! Using EEG and EOG measurements for cognitive overload detection in a simulated industrial context. Appl Ergon. 2022 Jul;102:103763. doi: 10.1016/j.apergo.2022.103763. Epub 2022 Apr 8.
• Molefi E, McLoughlin I, Palaniappan R. On the potential of transauricular electrical stimulation to reduce visually induced motion sickness. Sci Rep. 2023 Feb 25;13(1):3272. doi: 10.1038/s41598-023-29765-9.
• Miller AL, Unsworth N. Variation in attention at encoding: Insights from pupillometry and eye gaze fixations. J Exp Psychol Learn Mem Cogn. 2020 Dec;46(12):2277-2294. doi: 10.1037/xlm0000797. Epub 2019 Nov 21.
• Mercante B, Deriu F, Rangon CM. Auricular Neuromodulation: The Emerging Concept beyond the Stimulation of Vagus and Trigeminal Nerves. Medicines (Basel). 2018 Jan 21;5(1):10. doi: 10.3390/medicines5010010.
• Landolt K, Maruff P, Horan B, Kingsley M, Kinsella G, O'Halloran PD, Hale MW, Wright BJ. Chronic work stress and decreased vagal tone impairs decision making and reaction time in jockeys. Psychoneuroendocrinology. 2017 Oct;84:151-158. doi: 10.1016/j.psyneuen.2017.07.238. Epub 2017 Jul 14.
• Hossain MB, Kong Y, Posada-Quintero HF, Chon KH. Comparison of Electrodermal Activity from Multiple Body Locations Based on Standard EDA Indices' Quality and Robustness against Motion Artifact. Sensors (Basel). 2022 Apr 21;22(9):3177. doi: 10.3390/s22093177.
• Hirten RP, Lin KC, Whang J, Shahub S, Churcher NKM, Helmus D, Muthukumar S, Sands B, Prasad S. Longitudinal monitoring of IL-6 and CRP in inflammatory bowel disease using IBD-AWARE. Biosens Bioelectron X. 2024 Feb;16:100435. doi: 10.1016/j.biosx.2023.100435. Epub 2024 Jan 6.
• Fortenbaugh FC, DeGutis J, Esterman M. Recent theoretical, neural, and clinical advances in sustained attention research. Ann N Y Acad Sci. 2017 May;1396(1):70-91. doi: 10.1111/nyas.13318. Epub 2017 Mar 5.
• Espinoza-Palavicino T, Mena-Chamorro P, Albayay J, Doussoulin A, Galvez-Garcia G. The use of transcutaneous Vagal Nerve Stimulation as an effective countermeasure for Simulator Adaptation Syndrome. Appl Ergon. 2023 Feb;107:103921. doi: 10.1016/j.apergo.2022.103921. Epub 2022 Oct 29.
• Eren OE, Filippopulos F, Sonmez K, Mohwald K, Straube A, Schoberl F. Non-invasive vagus nerve stimulation significantly improves quality of life in patients with persistent postural-perceptual dizziness. J Neurol. 2018 Oct;265(Suppl 1):63-69. doi: 10.1007/s00415-018-8894-8. Epub 2018 May 21.
• Colzato L, Beste C. A literature review on the neurophysiological underpinnings and cognitive effects of transcutaneous vagus nerve stimulation: challenges and future directions. J Neurophysiol. 2020 May 1;123(5):1739-1755. doi: 10.1152/jn.00057.2020. Epub 2020 Mar 25.
• Chuang CC, Ye JJ, Lin WC, Lee KT, Tai YT. Photoplethysmography variability as an alternative approach to obtain heart rate variability information in chronic pain patient. J Clin Monit Comput. 2015 Dec;29(6):801-6. doi: 10.1007/s10877-015-9669-8. Epub 2015 Feb 24.
• Cegarra J, Valery B, Avril E, Calmettes C, Navarro J. OpenMATB: A Multi-Attribute Task Battery promoting task customization, software extensibility and experiment replicability. Behav Res Methods. 2020 Oct;52(5):1980-1990. doi: 10.3758/s13428-020-01364-w.
• Babic T, Browning KN. The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur J Pharmacol. 2014 Jan 5;722:38-47. doi: 10.1016/j.ejphar.2013.08.047. Epub 2013 Oct 31.
• Lindsay GW. Attention in Psychology, Neuroscience, and Machine Learning. Front Comput Neurosci. 2020 Apr 16;14:29. doi: 10.3389/fncom.2020.00029. eCollection 2020.
• Baxter AL, Watcha MF, Baxter WV, Leong T, Wyatt MM. Development and validation of a pictorial nausea rating scale for children. Pediatrics. 2011 Jun;127(6):e1542-9. doi: 10.1542/peds.2010-1410. Epub 2011 May 29.

Helpful Links

• OpenBCI Galea biosensing headset website
• Sparrow link device website

Study record dates

Study Major Dates

• Study Start (Actual): April 30, 2025
• Primary Completion (Actual): February 13, 2026
• Study Completion (Actual): March 15, 2026

Study Registration Dates

• First Submitted: January 13, 2025
• First Submitted That Met QC Criteria: January 16, 2025
• First Posted (Actual): January 17, 2025

Study Record Updates

• Last Update Posted (Actual): April 6, 2026
• Last Update Submitted That Met QC Criteria: March 31, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: stress; cognitive performance; neurostimulation; attention; cybersickness; biosensing
• Other Study ID Numbers: OBCI-CAMSAN-01 20241050; FA238423PB017 (Other Grant/Funding Number: USAF)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No